Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus
NCT ID: NCT00002706
Last Updated: 2015-05-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
2616 participants
INTERVENTIONAL
1996-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Laparoscopic Approach to Cervical Cancer
NCT00614211
Endometrial Carcinoma: Comparison of Surgical Approaches (Laparoscopy vs Laparotomy)
NCT06790004
Comparison of Five-year Survival and Disease-free Survival in Patients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy With and Without Uterine Manipulator
NCT06307886
Endometrial Cancer and Robotic-assisted Versus Traditional Laparoscopy
NCT01466777
Comparison of Prognosis in Endometrial Cancer Treated With Different Surgical Methods: Laparoscopy, Robotic-assisted Laparoscopy and Laparotomy
NCT05969405
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Compare the incidence of surgical complications, peri-operative morbidity, and mortality in patients with stage I or IIa, grade I-III endometrial cancer or uterine cancer undergoing surgical staging through laparoscopic assisted vaginal hysterectomy vs total abdominal hysterectomy.
II. Compare the length of hospital stay after surgery in patients receiving these treatments.
III. Compare the quality of life of patients receiving these treatments. IV. Compare the incidence and location of disease recurrence in patients receiving these treatments.
OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients undergo vaginal hysterectomy and bilateral salpingo-oophorectomy (BSO) via laparoscopy.
ARM II: Patients undergo total abdominal hysterectomy and BSO via conventional laparotomy.
Patients in both arms also undergo pelvic and para-aortic lymph node sampling. Quality of life is assessed at baseline, at 1, 3, and 6 weeks, and then at 6 months.
Patients are followed at 6 weeks, every 3 months for 2 years, and then every 6 months for 3 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I
Patients undergo vaginal hysterectomy and BSO via laparoscopy.
Laparoscopic Surgery
Undergo vaginal hysterectomy and BSO via laparoscopy
Quality-of-Life Assessment
Ancillary studies
Arm II
Patients undergo total abdominal hysterectomy and BSO via conventional laparotomy.
Quality-of-Life Assessment
Ancillary studies
Therapeutic Conventional Surgery
Undergo total abdominal hysterectomy and BSO via conventional laparotomy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Laparoscopic Surgery
Undergo vaginal hysterectomy and BSO via laparoscopy
Quality-of-Life Assessment
Ancillary studies
Therapeutic Conventional Surgery
Undergo total abdominal hysterectomy and BSO via conventional laparotomy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be considered a candidate for surgery
* No contraindication to laparoscopy
* No clinical or chest x-ray evidence of metastasis beyond the uterine corpus or macroscopic involvement of the endocervix
* Performance status - GOG 0-3
* WBC at least 3,000/mm\^3
* Platelet count at least 100,000/mm\^3
* Bilirubin no greater than 1.5 times normal
* SGOT no greater than 3 times normal
* Creatinine no greater than 2.0 mg/dL
* Prior malignancy allowed if no current evidence of disease
* Not pregnant
* No prior pelvic or abdominal radiotherapy
* See Disease Characteristics
* No prior retroperitoneal surgery
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Gynecologic Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joan Walker
Role: PRINCIPAL_INVESTIGATOR
Gynecologic Oncology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bishop EA, Java JJ, Moore KN, Spirtos NM, Pearl ML, Zivanovic O, Kushner DM, Backes F, Hamilton CA, Geller MA, Hurteau J, Mathews C, Wenham RM, Ramirez PT, Zweizig S, Walker JL. Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol. 2018 Jan;218(1):109.e1-109.e11. doi: 10.1016/j.ajog.2017.09.026. Epub 2017 Oct 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2012-02237
Identifier Type: REGISTRY
Identifier Source: secondary_id
CDR0000064513
Identifier Type: -
Identifier Source: secondary_id
GOG-LAP2
Identifier Type: OTHER
Identifier Source: secondary_id
GOG-LAP2
Identifier Type: OTHER
Identifier Source: secondary_id
GOG-LAP2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.